PF-Atlas › Clinical Trials › NCT03939520
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
pirfenidone and nintedanib · Phase 4
Registry ID
NCT03939520
Phase
Phase 4
Status
Completed
Drug / intervention
pirfenidone and nintedanib
Sponsor
Hospices Civils de Lyon
Start
2020-06-11
About this trial
pirfenidone and nintedanib is evaluated in NCT03939520, a Phase 4 idiopathic pulmonary fibrosis study sponsored by Hospices Civils de Lyon. Current status: Completed.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03939520 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.